Innovac Therapeutics

What Innovac Therapeutics does

Innovac Therapeutics is a privately held, preclinical-stage biotechnology company founded in 2022 and headquartered in Cambridge, Massachusetts, with additional operations in Shanghai and Hangzhou, China. The company develops mRNA-LNP vaccines and therapeutics targeting oncology, infectious disease, and other indications with high unmet medical need, for the US, China, and global markets. Innovac has no commercial products or disclosed revenue and is advancing lead programs toward the clinical stage.

The company's core offering is an integrated mRNA-LNP platform composed of four modules: (i) a proprietary mRNA Design Platform using codon optimization, secondary-structure engineering, and 5'/3' UTR optimization to maximize translation efficiency and stability; (ii) a Delivery System Platform based on lipid nanoparticle (LNP) encapsulation, including internally discovered ionizable lipids with claimed patent protection; (iii) a Computational Platform for designing universal T-cell epitope vaccines that direct CD8+ and CD4+ T-cell responses; and (iv) end-to-end in-house manufacturing from plasmid production through fill/finish. This vertically integrated stack is intended to shorten concept-to-clinic timelines compared with biotechs reliant on contract development.

Innovac's business model is presently science-driven and partnership/financing-oriented rather than commercial. The company raises equity capital (notably a $18M Series Pre-A in September 2023 led by Elikon Venture, Vision Plus Capital, Yunion Healthcare Ventures, and TG Sino-Dragon Fund) and assembles strategic talent and SAB relationships to validate and advance its pipeline. Pricing is not publicly disclosed because no products are sold; customer-facing activity is limited to inbound corporate email and a website contact channel. End customers, once products reach market, are expected to be patient populations with oncology and infectious disease indications in the US, China, and global markets.

Name

Innovac Therapeutics

Legal name

Innovac Therapeutics

Website

https://innovactx.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Innovac Therapeutics is a preclinical-stage biotechnology company developing an integrated mRNA-LNP platform — spanning mRNA design, lipid nanoparticle delivery, computational T-cell epitope vaccine design, and end-to-end manufacturing — to produce therapeutic and prophylactic vaccines for oncology, infectious disease, and other high-unmet-need indications across the US, China, and global markets.

Ownership category

akta.pro rank

Product category

mRNA Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

akta.pro secondary industries

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB), mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

Keywords

• MRNA vaccines
• Lipid nanoparticles
• Therapeutic vaccines
• Cancer immunotherapy
• Infectious disease vaccines

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Innovac Therapeutics develops proprietary mRNA-LNP vaccines and therapeutics for cancer, infectious diseases, and other indications with high unmet medical need. Its integrated platform combines computational mRNA design (codon and UTR optimization), lipid nanoparticle delivery (with internally discovered, patentable ionizable lipids), a proprietary computational package for designing universal T-cell epitope vaccines, and end-to-end mRNA-LNP manufacturing from plasmid through fill/finish.

Product overview

Innovac Therapeutics offers a single integrated mRNA-LNP platform-plus-modules architecture rather than a unified off-the-shelf product. The four named modules — the mRNA Design Platform (codon/UTR optimization), the Delivery System Platform (lipid nanoparticle encapsulation), the Computational Platform (universal T-cell epitope vaccine design), and End-to-End RNA Manufacturing — together feed the company's pipeline of Innovative mRNA Vaccines (therapeutic and prophylactic candidates) targeting oncology, infectious disease, and other unmet needs for the US, China, and global markets. The Computational and Design Platforms generate optimized mRNA sequences that are formulated into LNPs and manufactured in-house, shortening timelines from concept to clinic.

Differentiator

Problem solved

Functional benefit

Products and services

• Innovative mRNA Vaccines (Therapeutic & Prophylactic)
• mRNA-LNP Platform

Quantifiable outcome

• $18 million raised in Series Pre-A financing (September 2023) to advance lead programs to clinical stage
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

Three partnerships are on record, tiered senior scientific advisor.

• David Bernstein, MD (Scientific Advisory Board)senior scientific advisorStrategic or Co-development PartnerAppointed to Innovac's Scientific Advisory Board upon closing of the Series Pre-A financing (September 2023). Director of the Gamble Program at Cincinnati Children's Hospital and its Vaccine Testing and Evaluation Unit; Professor at the University of Cincinnati Department of Pediatrics. Brings vaccine testing and evaluation expertise.
• Shan Lu, MD, PhD (Scientific Advisory Board)senior scientific advisorStrategic or Co-development PartnerAppointed to Innovac's Scientific Advisory Board upon closing of the Series Pre-A financing (September 2023). Director of the Laboratory of Nucleic Acid Vaccines at the University of Massachusetts Medical School and Professor Emeritus at UMass Chan Medical School. Brings nucleic acid vaccine expertise.
• Elaine Mardis, PhD (Scientific Advisory Board)senior scientific advisorStrategic or Co-development PartnerAppointed to Innovac's Scientific Advisory Board upon closing of the Series Pre-A financing (September 2023). Director of the Institute for Genomic Medicine at Nationwide Children's Hospital; Professor of Pediatrics at The Ohio State University College of Medicine; key participant in the Cancer Genome Atlas development; AACR President 2019-2020. Brings genomics and oncology expertise.

Scale indicators4 records

Recent moves4 records

Expansion highlights5 records

Broad incumbents

• Moderna: The original mRNA-LNP platform company; Innovac's founders and Head of Comp Bio (Valiante, Breton) were alumni of Moderna's PCV (mRNA-4157) program. Directly comparable mRNA-LNP vaccine pipeline in oncology and infectious disease, but at vastly greater scale and with approved products.
• BioNTech: Germany-based mRNA therapeutics leader with oncology and infectious disease programs (BNT111, BNT122/iNeST) closely paralleling Innovac's cancer vaccine focus. Competes in the same personalized neoantigen and infectious disease vaccine categories.
• Translate Bio (Sanofi): mRNA therapeutics platform acquired by Sanofi in 2021 for use in vaccines and therapeutic proteins. Direct technology and modality overlap, though now embedded inside a large pharmaceutical company.
• CSL Seqirus: Major influenza and pandemic vaccine manufacturer with a global mRNA vaccine development program. Represents the established-vaccine-manufacturer archetype that an Innovac partnership or acquisition target would look like, with comparable end-market but a non-mRNA-native incumbent position.

Direct peers

• Caperna (Moderna venture): Moderna-venture personalized cancer vaccine spin-out where Innovac CSO Nicholas Valiante previously served as CSO. Closest direct comparator in personalized mRNA cancer vaccines, although Caperna is no longer operating as a stand-alone entity.
• CureVac: Early mRNA therapeutics company developing prophylactic and therapeutic mRNA vaccines for infectious disease and oncology using proprietary LNPs. Direct technology overlap and similar preclinical/early-clinical stage positioning in selected programs.
• Arcturus Therapeutics: Clinical-stage mRNA medicines company with proprietary LNP delivery technology (STARR self-amplifying RNA) and pipeline in infectious disease and rare liver diseases. Comparable mRNA-LNP modality and oncology/infectious disease focus.

Emerging players

• Kernal Biologics: mRNA therapeutics company developing cancer immunotherapies using selective mRNA translation in hematopoietic cells. Listed as a previous employer of Innovac's VP of Immunology, and operates in the same mRNA cancer immunotherapy niche.
• Beam Therapeutics: Base-editing therapeutic company where Innovac's Head of Computational Biology (Breton) previously worked. Operates in a different modality (base editing vs. mRNA) but shares Cambridge biotech ecosystem, computational biology talent pool, and oncology focus.
• Compass Therapeutics: Clinical-stage oncology company developing antibody-based immunotherapies; previous employer of Innovac's VP Immunology. Tangential peer — overlapping oncology immunotherapy customer segment rather than modality, and a relevant comparator for capital-efficient Cambridge biotechs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Innovac Therapeutics